RecruitingPhase 3NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Nemtabrutinib(drug)
- Enrollment
- 735 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2035
Study locations (30)
- Highlands Oncology Group ( Site 5405), Springdale, Arkansas, United States
- MemorialCare Health System - Long Beach Medical Center ( Site 5421), Long Beach, California, United States
- Memorial Hospital West ( Site 5410), Pembroke Pines, Florida, United States
- Oregon Health and Science University ( Site 5425), Portland, Oregon, United States
- Medical Oncology Associates, PS ( Site 5406), Spokane, Washington, United States
- University of Wisconsin Hospital and Clinics-Carbone Cancer Center ( Site 5423), Madison, Wisconsin, United States
- Instituto Alexander Fleming ( Site 1005), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
- Instituto de Investigaciones Clínicas Mar del Plata ( Site 1007), Mar del Plata, Buenos Aires, Argentina
- Sanatorio Parque ( Site 1003), Rosario, Santa Fe Province, Argentina
- Centro Medico Fleischer ( Site 1006), Buenos Aires, Argentina
- Hospital Aleman-oncohematologic diseases ( Site 1001), Buenos Aires, Argentina
- Royal Adelaide Hospital ( Site 1104), Adelaide, South Australia, Australia
- Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 1103), Melbourne, Victoria, Australia
- UZ Leuven-Hematology ( Site 1200), Leuven, Vlaams-Brabant, Belgium
- ZAS Cadix ( Site 1203), Antwerp, Belgium
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05947851 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn